BioSpace News Archive

Seevix Material Sciences Ltd., which develops and manufactures synthetic SVX™ spidersilk, announced today that it plans to use its patented spidersilk technology to create disposable and safe filters with high entrapment and inactivation efficacy to neutralize COVID-19 and other coronaviruses.

Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic

GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announces financial results for the first quarter ended March 31, 2020.

In an era of heightened awareness over viruses and contaminants, Advancing Medical Innovations (AMI) announced its client Performance Compounds Inside (PCI)'s novel 3PRE Technology can bring unprecedented antimicrobial protection to products within the healthcare industry – with little or no disruption to current manufacturing processes.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuant to its existing automatic shelf registration statement.

BioMarin Pharmaceutical Inc. announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated convertible notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Bausch Health Companies Inc. announced that it has priced and upsized its previously announced offering of $1,500,000,000 aggregate principal amount of 6.250% senior notes due 2029.

AVITA Medical Limited is pleased to announce that the Australian Securities and Investments Commission has registered the scheme booklet in relation to the proposed scheme of arrangement under which AVITA Therapeutics, Inc., a newly-formed company incorporated in Delaware in the United States of America, will become the parent company of the Company and its subsidiaries for the purposes of effecting a redomiciliation of the Avita Group from Australia to the United States of America.